Apellis Pharmaceuticals, Inc. (APLS)
22.28
-0.52
(-2.28%)
USD |
NASDAQ |
Feb 20, 16:00
22.07
-0.21
(-0.94%)
Pre-Market: 08:30
Apellis Pharmaceuticals Research and Development Expense (Quarterly) : 68.19M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amneal Pharmaceuticals, Inc. | 63.35M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Amicus Therapeutics, Inc. | 23.74M |
| Ionis Pharmaceuticals, Inc. | 217.13M |
| Sarepta Therapeutics, Inc. | 218.89M |